Bayer AG Stock (DE000BAY0017): FDA clearance for new MRI contrast agent keeps the stock in focus

Bayer stock is in focus after U.S. regulators cleared its new low-dose MRI contrast agent Gadoquatrane for use in the United States, while shares traded around 36.40 euros on XETRA.

By AD HOC NEWS - Companies & Analysis Desk Team | June 15, 2026

Bayer stock is in focus on Monday after the company said U.S. regulators cleared its low-dose MRI contrast agent Gadoquatrane for use in the United States. Finanzen.net reported the shares were up 0.58% at 36.40 euros on XETRA in early trade, while WELT cited a recent quote of 36.10 euros and a prior close of 36.19 euros.

Bayer's latest U.S. drug approval adds a fresh operating angle

The FDA decision gives Bayer another commercial item to point to at a time when investors are still weighing the company's broader legal overhang in the United States. Bayer said the agent is approved for detecting and visualizing lesions with abnormal vascular supply in the central nervous system and in other body regions across patients.

That approval matters because the market has been treating Bayer as a story split between operating progress and litigation risk. The company also reported first-quarter earnings momentum earlier this month, with earnings per share rising to 2.81 euros and operating income before special items increasing 9%, according to Aktiencheck.

Those figures suggest that Bayer's core businesses are still generating results, even as the legal debate around glyphosate continues to dominate the valuation discussion. Aktiencheck said roughly 65,000 glyphosate cases remain open, keeping the issue central for investors who track the stock.

Analyst commentary has stayed cautious but constructive. Berenberg recently lifted its price target to 40.50 euros from 40 euros and kept a Hold rating, while a finanzen.net roundup of May analyst views showed an average target of 48.82 euros and 9 buy ratings versus 2 hold ratings.

For U.S. investors, Bayer trades on the OTC market under the symbol BAYRY, while the Frankfurt-listed shares are the main reference point in Europe and the company remains tied to the healthcare and crop science sectors rather than a broad U.S. index membership story.

Key facts on Bayer stock

• Name: Bayer AG
• Industry: Pharmaceuticals, crop science, consumer health
• Headquarters: Leverkusen, Germany
• Core markets: Europe, the United States, and other global markets
• Revenue drivers: Prescription drugs, crop protection, seeds, and consumer health products
• Listing: Frankfurt Stock Exchange; U.S. OTC ticker BAYRY
• Trading currency: Euro, with U.S. OTC trading in U.S. dollars

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.